Hypermarcas (OTCMKTS:HYPMY) and Harrow (NASDAQ:HROW) Head to Head Contrast

Harrow (NASDAQ:HROW) and Hypermarcas (OTCMKTS:HYPMY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Risk & Volatility

Harrow has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Hypermarcas has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Harrow and Hypermarcas, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	8	0	2.64
Hypermarcas	0	1	0	1	3.00

Harrow presently has a consensus price target of $69.43, indicating a potential upside of 78.57%. Given Harrow’s higher possible upside, research analysts clearly believe Harrow is more favorable than Hypermarcas.

Valuation & Earnings

This table compares Harrow and Hypermarcas”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	5.32	-$5.14 million	($0.41)	-94.83
Hypermarcas	$1.38 billion	2.16	$213.10 million	$0.48	8.81

Hypermarcas has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Hypermarcas, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

72.8% of Harrow shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Harrow and Hypermarcas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Hypermarcas	19.41%	14.08%	6.91%

Summary

Hypermarcas beats Harrow on 9 of the 15 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About Hypermarcas

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.